Articles producció científica> Medicina i Cirurgia

Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study

  • Datos identificativos

    Identificador: imarina:5651845
    Autores:
    Jara-Palomares LSolier-Lopez AElias-Hernandez TAsensio-Cruz MBlasco-Esquivias IMarin-Barrera Lde la Borbolla-Artacho MPraena-Fernandez JMontero-Romero ENavarro-Herrero SSerrano-Gotarredona MSánchez-Díaz JPalacios COtero R
    Resumen:
    © 2017 The Author(s) Introduction The safety and efficacy of low-molecular-weight heparin (LMWH) treatment in patients with cancer-associated thrombosis (CAT) beyond 6 months are unknown. Our aim was to determine the safety of long-term tinzaparin use in patients with CAT. Methods We performed a prospective, open, single arm, multicentre study in patients with CAT receiving treatment with tinzaparin. We evaluated the rate of clinically relevant bleeding events (major and non-major clinically relevant bleeding) and venous thromboembolism (VTE) recurrence. Results A total of 247 patients were recruited, with a crude incidence of major bleeding of 4.9% (12/247). The rate of clinically relevant bleeding during months 1–6 and 7–12, was 0.9% [95% confidence interval (95% CI) 0.5 to 1.6%] and 0.6% (95% CI 0.2 to 1.4%) (p = 0.5) per patient and month, respectively. Male gender showed greater risk for clinically relevant bleeding with a hazard ratio (HR) of 2.97 (95% CI 1.01 to 8.1; p = 0.02). The incidence of VTE recurrence at months 1–6 and 7–12 was 4.5% (95% CI 2.2 to 7.8%) and 1.1% (95% CI 0.1 to 3.9%), respectively. One patient died due to VTE recurrence and two because of severe bleeding. Conclusions Treatment with tinzaparin beyond 6 months is safe in patients with CAT.
  • Otros:

    Autor según el artículo: Jara-Palomares L; Solier-Lopez A; Elias-Hernandez T; Asensio-Cruz M; Blasco-Esquivias I; Marin-Barrera L; de la Borbolla-Artacho M; Praena-Fernandez J; Montero-Romero E; Navarro-Herrero S; Serrano-Gotarredona M; Sánchez-Díaz J; Palacios C; Otero R
    Departamento: Medicina i Cirurgia
    Autor/es de la URV: Porras Ledantes, Jose Antonio
    Palabras clave: Venous thromboembolism Venous thromboembolic disease Vein thrombosis Tinzaparin Pulmonary-embolism Pulmonary embolism Prevention Practice guideline update Oral anticoagulants Molecular-weight heparin Management Low-molecular-weight heparin Cancer Antithrombotic therapy American society tinzaparin pulmonary embolism low-molecular-weight heparin cancer
    Resumen: © 2017 The Author(s) Introduction The safety and efficacy of low-molecular-weight heparin (LMWH) treatment in patients with cancer-associated thrombosis (CAT) beyond 6 months are unknown. Our aim was to determine the safety of long-term tinzaparin use in patients with CAT. Methods We performed a prospective, open, single arm, multicentre study in patients with CAT receiving treatment with tinzaparin. We evaluated the rate of clinically relevant bleeding events (major and non-major clinically relevant bleeding) and venous thromboembolism (VTE) recurrence. Results A total of 247 patients were recruited, with a crude incidence of major bleeding of 4.9% (12/247). The rate of clinically relevant bleeding during months 1–6 and 7–12, was 0.9% [95% confidence interval (95% CI) 0.5 to 1.6%] and 0.6% (95% CI 0.2 to 1.4%) (p = 0.5) per patient and month, respectively. Male gender showed greater risk for clinically relevant bleeding with a hazard ratio (HR) of 2.97 (95% CI 1.01 to 8.1; p = 0.02). The incidence of VTE recurrence at months 1–6 and 7–12 was 4.5% (95% CI 2.2 to 7.8%) and 1.1% (95% CI 0.1 to 3.9%), respectively. One patient died due to VTE recurrence and two because of severe bleeding. Conclusions Treatment with tinzaparin beyond 6 months is safe in patients with CAT.
    Áreas temáticas: Saúde coletiva Química Psicología Peripheral vascular disease Medicina iii Medicina ii Medicina i Interdisciplinar Hematology General medicine Farmacia Ensino Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología Biodiversidade Astronomia / física
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 00493848
    Direcció de correo del autor: joseantonio.porras@urv.cat
    Identificador del autor: 0000-0001-6418-1822
    Fecha de alta del registro: 2024-09-07
    Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
    Enlace a la fuente original: https://www.sciencedirect.com/science/article/pii/S0049384817304061
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referencia al articulo segun fuente origial: Thrombosis Research. 157 90-96
    Referencia de l'ítem segons les normes APA: Jara-Palomares L; Solier-Lopez A; Elias-Hernandez T; Asensio-Cruz M; Blasco-Esquivias I; Marin-Barrera L; de la Borbolla-Artacho M; Praena-Fernandez J (2017). Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study. Thrombosis Research, 157(), 90-96. DOI: 10.1016/j.thromres.2017.07.004
    DOI del artículo: 10.1016/j.thromres.2017.07.004
    Entidad: Universitat Rovira i Virgili
    Año de publicación de la revista: 2017
    Tipo de publicación: Journal Publications
  • Palabras clave:

    Hematology,Peripheral Vascular Disease
    Venous thromboembolism
    Venous thromboembolic disease
    Vein thrombosis
    Tinzaparin
    Pulmonary-embolism
    Pulmonary embolism
    Prevention
    Practice guideline update
    Oral anticoagulants
    Molecular-weight heparin
    Management
    Low-molecular-weight heparin
    Cancer
    Antithrombotic therapy
    American society
    tinzaparin
    pulmonary embolism
    low-molecular-weight heparin
    cancer
    Saúde coletiva
    Química
    Psicología
    Peripheral vascular disease
    Medicina iii
    Medicina ii
    Medicina i
    Interdisciplinar
    Hematology
    General medicine
    Farmacia
    Ensino
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Biotecnología
    Biodiversidade
    Astronomia / física
  • Documentos:

  • Cerca a google

    Search to google scholar